-
Innovation Ranking
NewInnovation Ranking – Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc (Inovio) is a biotechnology company that focuses on developing DNA immunotherapies and vaccines for the treatment and prevention of various cancers and infectious diseases. The company develops products based on its core SynCon DNA plasmid technology and electroporation delivery technology. Its product pipeline includes VGX-3100 for the treatment of cervical HSIL, vulvar HSIL, anal HSIL; INO-5401 for glioblastoma; and INO-3107 for recurrent respiratory papillomatosis (RRP). The company is also engaged in development programs in partnership with several...
-
Product Insights
NewNet Present Value Model: Inovio Pharmaceuticals Inc’s INO-5401
Empower your strategies with our Net Present Value Model: Inovio Pharmaceuticals Inc's INO-5401 report and make more profitable business decisions.Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: Inovio Pharmaceuticals Inc’s INO-3107
Empower your strategies with our Net Present Value Model: Inovio Pharmaceuticals Inc's INO-3107 report and make more profitable business decisions.Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: Inovio Pharmaceuticals Inc’s (Bizalimogene ralaplasmid + Mavilimogene ralaplasmid)
Empower your strategies with our Net Present Value Model: Inovio Pharmaceuticals Inc's (Bizalimogene ralaplasmid + Mavilimogene ralaplasmid) report and make more profitable business decisions.Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Company Insights
Innovation and Patenting activity of Inovio Pharmaceuticals Inc Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of Inovio Pharmaceuticals Inc Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be...
-
Product Insights
NewNet Present Value Model: F. Hoffmann-La Roche Ltd’s Dirloctocogene Samoparvovec
Empower your strategies with our Net Present Value Model: F. Hoffmann-La Roche Ltd's Dirloctocogene Samoparvovec report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – INO-6160 in Human Immunodeficiency Virus (HIV) Infections (AIDS)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - INO-6160 in Human Immunodeficiency Virus (HIV) Infections (AIDS) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. INO-6160 in Human Immunodeficiency Virus (HIV) Infections...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – INO-5401 in Glioblastoma Multiforme (GBM)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - INO-5401 in Glioblastoma Multiforme (GBM) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. INO-5401 in Glioblastoma Multiforme (GBM) Drug Details: INO-5401 is under development...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Durvalumab in Medullary Thyroid Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Durvalumab in Medullary Thyroid Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Durvalumab in Medullary Thyroid Cancer Drug Details: Durvalumab (MEDI-4736, Imfinzi, Fidursi,...
-
Product Insights
Recurrent Respiratory Papillomatosis (Juvenile Laryngeal Papilloma or Laryngeal Papilloma) – Drugs In Development, 2023
Global Markets Direct’s, ‘Recurrent Respiratory Papillomatosis (Juvenile Laryngeal Papilloma or Laryngeal Papilloma) - Drugs In Development, 2023’, provides an overview of the Recurrent Respiratory Papillomatosis (Juvenile Laryngeal Papilloma or Laryngeal Papilloma) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Recurrent Respiratory Papillomatosis (Juvenile Laryngeal Papilloma or Laryngeal Papilloma), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological...